Background: Women and girls who have undergone type III female genital mutilation
| INTRODUCTION
Female genital mutilation (FGM) can be divided into four types according to the classification developed by the WHO.
1 Type III FGM, also known as infibulation, involves the cutting of the labia minora, the inner lining of the labia majora with or without excision of the clitoris, and subsequent stitching of these structures together creating a small opening through which urine and menstrual blood can flow. 2 It is the most severe form of FGM and is reported to affect about 10% of women (over 8 million), especially in the north eastern part of Africa. 3 Complications related to FGM increase as the procedure becomes more extensive. 1, 4 Urologic complications associated with FGM may include acute urine retention and chronic disorders such as urinary tract obstruction (from urethral meatus stenosis and urethral stricture), urinary incontinence, urethral injuries, as well as urinary tract infections. postoperative pain, irritation of the raw areas by urine, and obstruction of the external urethral meatus by skin flaps or blood clots. Infibulation may result in poor urine flow, painful passage of urine, and repeated urinary tract infections. [9] [10] [11] In addition, where very extensive infibulation involving closure of the urethral opening has occurred, the urinary stream first impinges on the fused labia minora and then exits through the narrowed opening in the vulva causing urinary splashing around the perineum and upper thighs.
The risk of recurrent urinary tract infections (UTIs) has been reported to be common in women and girls living with FGM 12 and is most common among those who have undergone type III FGM.
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Partial occlusion of the vagina and the urethra results in a continuously wet perineum with ascension of bacterial organisms into the urinary tract. 16 When not treated appropriately and in a timely manner, infections in the urinary tract can ascend to the kidneys (pyelonephritis) and may cause septicemia with increased risk of death. Furthermore, stones may form in the urethra 17 or bladder leading to further obstruction.
18
Another clinical problem associated with type III FGM is the difficulty associated with catheterization of affected women to relieve urinary retention intrapartum or in other circumstances. 19 Some women have been known to develop overactive bladder following infibulation. The procedure can be done in an outpatient specialist clinic using a local anesthetic agent. For adult women, a single study suggests that the procedure is best performed before pregnancy but may be carried out between 20-28 weeks of pregnancy, or during labor. 21 There remains an evidence gap on the best timing for deinfibulation 22 Partial or total deinfibulation, either alone or in combination with urological surgeries, may have wide-ranging beneficial effects on several complications related to type III FGM. 23 In women with urinary tract obstruction and recurrent infections, the procedure is performed to minimize the risk of damage to the kidneys. Deinfibulation can also facilitate bladder emptying thereby lessening the risk of urinary retention and chronic recurrent urinary tract infections associated with type III FGM. 15 In this regard, some women have been reported to mistake the dramatic improvement in ease of urination that tends to follow deinfibulation for incontinence.
24
Although antibiotics are used for the treatment of the UTIs, deinfibulation is believed to reduce the risk of chronic recurrent UTIs in women with type III FGM in whom prophylactic antibiotics may not be effective. 15 To relieve urethral strictures, deinfibulation may be combined with extra procedures such as dilatation or repair (urethroplasty)
to ease the obstruction. Urethral catheterization has been used in the relief of acute urine retention although this may be difficult owing to the presence of scar tissue around the urethral opening. Biofeedback techniques and counselling have also been used in the treatment of urinary incontinence and frequency arising from overactive bladder.
19
Anticholinergic agents alone or in combination with other interventions have been reported to be effective in treating urinary incontinence from other causes and may be useful in this population.
25
This systematic review aims to summarize the evidence on the effectiveness of deinfibulation in treating or preventing urologic complications of FGM such as urine retention, urinary incontinence, urinary tract infections, and urethral stricture in order to inform current practice guidelines and policy.
| MATERIAL AND METHODS
For the review, the following study types were considered for inclu- We initially conducted a broad preliminary search of the databases for studies related to FGM using a set of predefined search terms. The terms comprised a combination of key words and MeSH terms (detailed search strategy is available upon request from the corresponding author). We then carried out an additional search with specific keywords Register of Systematic Reviews (PROSPERO) with registration number CRD42015024901.
| RESULTS
The search identified 2573 records from electronic databases. We excluded 59 duplicate records. The remaining 2514 articles were screened, after which four potentially relevant studies were identified.
Upon review of the full text of these four articles, none met our inclusion criteria (Fig. 1) . Three studies were excluded because they were single case reports where deinfibulation was performed and there were no comparative cases. 17, 20, 27 The remaining study was excluded because the intervention was defined as urethral catheterization, as opposed to deinfibulation.
28

| DISCUSSION
Type III FGM is associated with a number of urologic complications. A recent systematic review identified urine retention and recurrent UTIs as the most common immediate and long-term complications following FGM. 12 In this review, we did not identify any studies assessing the effectiveness of deinfibulation for the prevention or treatment of these complications. Limited indirect evidence, mainly from case reports, suggests that surgical reconstruction can lead to an amelioration of infections related to urinary tract symptoms. 29 Nevertheless, it would appear that the current practice of deploying interventions for urologic complications is predominantly informed by anecdotal reports and occasional case reports.
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The absence of intervention studies may be due to the fact that most FGM-related research is limited to countries where the practice is prevalent, and for which it may not be a national research priority.
It may also be related to paucity of funding for such studies. Often, research in lower-and middle-income countries is donor driven and funded. Consequently, national research priorities may not be aligned with donor priorities.
31
Proper identification of women with type III FGM is a key initial step in diagnosing urologic complications. However, studies suggest that health workers in high-, low-, and middle-income countries are ill-prepared to correctly identify and appropriately classify the FGM types. 32, 33 This presents missed opportunities to diagnose urologic complications in such women for whom early deinfibulation may be warranted. Given current trends in immigration, it is expected that many more women with type III FGM will seek care in Western countries in the near future.
The greatest threat to the validity of the review is likelihood of publication bias, given that studies that did not find the intervention to be effective may not have been published. However, we were unable to assess this possibility. In addition, while we did not apply any language limitations, it is still possible that we missed some potentially relevant reports in the grey 
| IMPLICATIONS FOR RESEARCH
The absence of RCTs of any interventions for urologic complications of type III FGM as shown by this extensive literature search is surprising considering the prevalent nature of FGM. Research is needed in this area. Well-designed, adequately powered, preferably multicenter collaborative trials may be needed to achieve this. The focus should be on the most frequent urologic morbidities such as incontinence, obstruction, and recurrent infections. Outcomes to be assessed in these trials should be such as would address the needs and concerns of patients, caregivers, and health providers in a truly contextual way. Complications F I G U R E 1 Flow diagram of identified studies.
